Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice.

Kohler H, Latteyer S, Hönes GS, Theurer S, Liao XH, Christoph S, Zwanziger D, Schulte JH, Kero J, Undeutsch H, Refetoff S, Schmid KW, Führer D, Moeller LC.

Thyroid. 2019 Oct;29(10):1438-1446. doi: 10.1089/thy.2018.0526. Epub 2019 Oct 8.

PMID:
31526103
2.

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.

Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, Grunewald L, Zirngibl F, Flemmig C, Jensen MC, Rossig C, Joussen A, Henssen A, Eggert A, Schulte JH, Künkele A.

BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.

3.

ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL.

Schlegel P, Jung G, Lang AM, Döring M, Schulte JH, Ebinger M, Holzer U, Heubach F, Seitz C, Lang B, Hundsdörfer P, Eggert A, Eichholz T, Kreyenberg H, Lang P, Handgretinger R.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):689-693. doi: 10.1038/s41409-019-0606-1.

PMID:
31431707
4.

HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches.

Oevermann L, Schulte JH, Hundsdörfer P, Hakimeh D, Kogel F, Lang P, Corbacioglu S, Eggert A, Sodani P.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):743-748. doi: 10.1038/s41409-019-0598-x. Review.

PMID:
31431703
5.

Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model.

Thole TM, Toedling J, Sprüssel A, Pfeil S, Savelyeva L, Capper D, Messerschmidt C, Beule D, Groeneveld-Krentz S, Eckert C, Gambara G, Henssen AG, Finkler S, Schulte JH, Sieber A, Bluethgen N, Regenbrecht CRA, Künkele A, Lodrini M, Eggert A, Deubzer HE.

Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32572. [Epub ahead of print]

PMID:
31304977
6.

Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease.

Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, Hofmann P, Aslanidis C, Lang P, Holler E, Eggert A, Corbacioglu S.

Bone Marrow Transplant. 2019 Nov;54(11):1859-1867. doi: 10.1038/s41409-019-0550-0. Epub 2019 May 14.

PMID:
31089288
7.

Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia.

Vivancos Stalin L, Gualandi M, Schulte JH, Renella R, Shakhova O, Mühlethaler-Mottet A.

Front Oncol. 2019 Apr 16;9:275. doi: 10.3389/fonc.2019.00275. eCollection 2019.

8.

Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma.

MacArthur IC, Bei Y, Garcia HD, Ortiz MV, Toedling J, Klironomos F, Rolff J, Eggert A, Schulte JH, Kentsis A, Henssen AG.

JCI Insight. 2019 Apr 18;5. pii: 127130. doi: 10.1172/jci.insight.127130.

9.

Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications.

Oevermann L, Zimmermann C, Voigt S, Künkele A, Lobitz S, Eggert A, Schulte JH, Kaufer BB, Deubzer HE.

Bone Marrow Transplant. 2019 Apr 15. doi: 10.1038/s41409-019-0530-4. [Epub ahead of print] No abstract available.

PMID:
30988380
10.

The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.

Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte JH, Bachmann HS.

BMC Cancer. 2019 Mar 18;19(1):243. doi: 10.1186/s12885-019-5439-1.

11.

Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.

Han Y, Lindner S, Bei Y, Garcia HD, Timme N, Althoff K, Odersky A, Schramm A, Lissat A, Künkele A, Deubzer HE, Eggert A, Schulte JH, Henssen AG.

Cancer Lett. 2019 Mar 31;445:24-33. doi: 10.1016/j.canlet.2018.12.012. Epub 2019 Jan 4.

PMID:
30611741
12.

A mechanistic classification of clinical phenotypes in neuroblastoma.

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M.

Science. 2018 Dec 7;362(6419):1165-1170. doi: 10.1126/science.aat6768.

PMID:
30523111
13.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2019 Apr;38(15):2690-2705. doi: 10.1038/s41388-018-0595-3. Epub 2018 Dec 11.

PMID:
30538293
14.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

15.

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.

Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, Van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F.

Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9.

16.

LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model.

Meder L, König K, Dietlein F, Macheleidt I, Florin A, Ercanoglu MS, Rommerscheidt-Fuss U, Koker M, Schön G, Odenthal M, Klein F, Büttner R, Schulte JH, Heukamp LC, Ullrich RT.

Oncogene. 2018 May;37(20):2746-2756. doi: 10.1038/s41388-018-0158-7. Epub 2018 Mar 5.

PMID:
29503447
17.

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P.

Oncotarget. 2017 Dec 18;9(2):2304-2319. doi: 10.18632/oncotarget.23409. eCollection 2018 Jan 5.

18.

The Expanding World of N-MYC-Driven Tumors.

Rickman DS, Schulte JH, Eilers M.

Cancer Discov. 2018 Feb;8(2):150-163. doi: 10.1158/2159-8290.CD-17-0273. Epub 2018 Jan 22. Review.

19.

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors.

Henssen AG, Reed C, Jiang E, Garcia HD, von Stebut J, MacArthur IC, Hundsdoerfer P, Kim JH, de Stanchina E, Kuwahara Y, Hosoi H, Ganem NJ, Dela Cruz F, Kung AL, Schulte JH, Petrini JH, Kentsis A.

Sci Transl Med. 2017 Nov 1;9(414). pii: eaam9078. doi: 10.1126/scitranslmed.aam9078.

20.

Life-threatening systemic rotavirus infection after vaccination in severe combined immunodeficiency (SCID).

Rosenfeld L, Mas Marques A, Niendorf S, Hofmann J, Gratopp A, Kühl JS, Schulte JH, von Bernuth H, Voigt S.

Pediatr Allergy Immunol. 2017 Dec;28(8):841-843. doi: 10.1111/pai.12771. Epub 2017 Oct 9. No abstract available.

PMID:
28815852
21.

From class waivers to precision medicine in paediatric oncology.

Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Review.

PMID:
28677575
22.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
23.

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.

Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A.

Klin Padiatr. 2017 May;229(3):147-167. doi: 10.1055/s-0043-103086. Epub 2017 May 30.

PMID:
28561228
24.

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A.

Oncotarget. 2017 Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840.

25.

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.

Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH.

Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268.

26.

Targeting tachykinin receptors in neuroblastoma.

Henssen AG, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, Speleman F, Schäfers S, De Preter K, Astrahanseff K, Struck J, Schramm A, Eggert A, Bergmann A, Schulte JH.

Oncotarget. 2017 Jan 3;8(1):430-443. doi: 10.18632/oncotarget.13440.

27.

Towards diagnostic application of non-coding RNAs in neuroblastoma.

Althoff K, Schulte JH, Schramm A.

Expert Rev Mol Diagn. 2016 Dec;16(12):1307-1313. Epub 2016 Nov 15. Review.

PMID:
27813435
28.

Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.

Fielitz K, Althoff K, De Preter K, Nonnekens J, Ohli J, Elges S, Hartmann W, Klöppel G, Knösel T, Schulte M, Klein-Hitpass L, Beisser D, Reis H, Eyking A, Cario E, Schulte JH, Schramm A, Schüller U.

Oncotarget. 2016 Nov 15;7(46):74415-74426. doi: 10.18632/oncotarget.12766.

29.

Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.

Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.

Clin Exp Ophthalmol. 2017 Apr;45(3):288-296. doi: 10.1111/ceo.12838. Epub 2016 Nov 10.

PMID:
27647547
30.

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, von Deimling A, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE.

Oncotarget. 2016 Oct 11;7(41):66344-66359. doi: 10.18632/oncotarget.11662.

31.

Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jürgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wößmann W, Nathrath M, Bielack SS, Frühwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O.

Eur J Cancer. 2016 Sep;65:91-101. doi: 10.1016/j.ejca.2016.06.009. Epub 2016 Jul 29.

PMID:
27479119
32.

Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma.

Büchel G, Schulte JH, Harrison L, Batzke K, Schüller U, Hansen W, Schramm A.

Oncoimmunology. 2016 Feb 18;5(5):e1131378. doi: 10.1080/2162402X.2015.1131378. eCollection 2016 May.

33.

Overexpression of Lin28b in Neural Stem Cells is Insufficient for Brain Tumor Formation, but Induces Pathological Lobulation of the Developing Cerebellum.

Wefers AK, Lindner S, Schulte JH, Schüller U.

Cerebellum. 2017 Feb;16(1):122-131. doi: 10.1007/s12311-016-0774-0.

PMID:
27039094
34.

The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.

Riehl LM, Schulte JH, Mulaw MA, Dahlhaus M, Fischer M, Schramm A, Eggert A, Debatin KM, Beltinger C.

Oncotarget. 2016 Feb 9;7(6):6620-5. doi: 10.18632/oncotarget.6776.

35.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

36.

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH.

Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2.

37.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.

Cancer Res. 2015 Dec 1;75(23):5143-54. doi: 10.1158/0008-5472.CAN-15-0423. Epub 2015 Oct 15.

38.

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann JM, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Gloeckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M.

Nature. 2015 Oct 29;526(7575):700-4. doi: 10.1038/nature14980. Epub 2015 Oct 14.

39.

The Lin28/let-7 axis is critical for myelination in the peripheral nervous system.

Gökbuget D, Pereira JA, Bachofner S, Marchais A, Ciaudo C, Stoffel M, Schulte JH, Suter U.

Nat Commun. 2015 Oct 14;6:8584. doi: 10.1038/ncomms9584.

40.

Neuroblastoma.

Schulte JH, Eggert A.

Crit Rev Oncog. 2015;20(3-4):245-70. Review.

PMID:
26349419
41.

Development of Port-Site Metastases Following Thoracoscopic Resection of a Neuroblastoma.

Pentek F, Schulte JH, Schweiger B, Metzelder M, Schündeln MM.

Pediatr Blood Cancer. 2016 Jan;63(1):149-51. doi: 10.1002/pbc.25677. Epub 2015 Jul 23.

PMID:
26206749
42.

Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma.

Lindner S, Bachmann HS, Odersky A, Schaefers S, Klein-Hitpass L, Hero B, Fischer M, Eggert A, Schramm A, Schulte JH.

Biomed Rep. 2015 Jul;3(4):443-446. Epub 2015 May 13.

43.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

Beckers A, Van Peer G, Carter DR, Gartlgruber M, Herrmann C, Agarwal S, Helsmoortel HH, Althoff K, Molenaar JJ, Cheung BB, Schulte JH, Benoit Y, Shohet JM, Westermann F, Marshall GM, Vandesompele J, De Preter K, Speleman F.

Cancer Lett. 2015 Sep 28;366(1):123-32. doi: 10.1016/j.canlet.2015.06.015. Epub 2015 Jun 26.

44.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

45.

Mutational dynamics between primary and relapse neuroblastomas.

Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH.

Nat Genet. 2015 Aug;47(8):872-7. doi: 10.1038/ng.3349. Epub 2015 Jun 29.

PMID:
26121086
46.

Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.

Schwermer M, Lee S, Köster J, van Maerken T, Stephan H, Eggert A, Morik K, Schulte JH, Schramm A.

Oncotarget. 2015 Jun 20;6(17):15425-35.

47.

Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.

Emdal KB, Pedersen AK, Bekker-Jensen DB, Tsafou KP, Horn H, Lindner S, Schulte JH, Eggert A, Jensen LJ, Francavilla C, Olsen JV.

Sci Signal. 2015 Apr 28;8(374):ra40. doi: 10.1126/scisignal.2005769.

PMID:
25921289
48.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

49.

IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.

Bell JL, Turlapati R, Liu T, Schulte JH, Hüttelmaier S.

J Clin Oncol. 2015 Apr 10;33(11):1285-93. doi: 10.1200/JCO.2014.55.9880. Epub 2015 Mar 9.

PMID:
25753434
50.

Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre.

Künkele A, Wilm J, Holdt M, Lohmann D, Bornfeld N, Eggert A, Temming P, Schulte JH.

Br J Ophthalmol. 2015 Jul;99(7):949-53. doi: 10.1136/bjophthalmol-2014-306222. Epub 2015 Jan 12.

PMID:
25583279

Supplemental Content

Loading ...
Support Center